ZELNORM NEWS
What is Zelnorm? |
The Study | Cardiovascular Side
Effects | Other Side Effects
| The FDA’s Reaction |
What To Do | Zelnorm News
 The Money Times | No Earnings Holes for Novartis Motley Fool - For instance, Novartis had to pull one of its top pharmaceutical drugs, irritable-bowel-syndrome treatment Zelnorm, from the US market in the beginning of ... Novartis posts 10% rise in first-quarter profit Novartis first quarter profits up 10% UPDATE: Shares Of Novartis Rise As First-quarter Profit Tops Forecast |
Takeda, Sucampo Get Expanded Indication for Amitiza FDA news (subscription), VA - Sucampo said it hopes Amitiza will fill the void left by Novartis’ Zelnorm (tegaserod), which was pulled from the market last year due to safety reasons. ... |
Sucampo's Amitiza Gets FDA Nod in IBS with Constipation BioWorld Online, GA - That means it is expected to fare better than Zelnorm, a 5-HT4 receptor partial agonist, which Basel, Switzerland-based Novartis voluntarily removed from ... |
 Seeking Alpha | Sucampo and Takeda's Newly Approved IBS Drug Is Sexy To Investors Seeking Alpha, NY - Since the withdrawal of the 5-HT4 agonist, Zelnorm (tegaserod), by Novartis (NVS) in March of last year due to possible heart risks, there has been no ... |
Monthly movement not normal Northern Daily News, Canada - I am taking Zelnorm and milk of magnesia but still have a bowel movement only once a month, usually at the time my period starts. It is very painful to pass ... |
FDA Approves Lubiprostone (Amitiza) for Women with IBS with ... MedPage Today, NJ - Tegaserod (Zelnorm), the IBS-C drug pulled from the market a year ago, is available under an investigational new drug protocol plan that permits its use in ... |
Novartis' Sweet Pill Forbes, NY - Novartis was recently forced to withdraw Zelnorm, a treatment for irritable bowel syndrome, from the United States market, following concerns about possible ... Novartis Q1 earnings beat forecasts, confirms outlook UPDATE |
Vaccines pump up Novartis 1Q profits; US sales down The Associated Press - This, combined with the withdrawal of its bowel drug Zelnorm from the US market, contributed to a 19 percent drop in US sales. ... |
Novartis shares soar as first-quarter profits beat forecasts Pharma Times (subscription), UK - Novartis is also still suffering from the the market withdrawal of the irritable bowel syndrome drug Zelnorm (tegaserod), sales of which were down 98% to ... |
Novartis names new chief for US drug business The Star-Ledger - NJ.com, NJ - ... States in the past year, including regulatory delays for its diabetes drug Galvus and the market withdrawal of its irritable bowel treatment Zelnorm. ... Novartis subsidiary gets new leader |
| If you or a loved one suffered a heart attack, stroke, or other serious injury while taking Zelnorm, you may wish to contact a qualified attorney who can evaluate your case to determine the best way to protect your legal rights. You may be entitled to compensation for your losses and suffering. Please contact our office to speak to a Zelnorm Attorney today for a free consultation. |
